Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Grazax® Treatment Compliance

This study has been completed.
Information provided by:
ALK-Abelló A/S Identifier:
First received: February 16, 2006
Last updated: September 29, 2008
Last verified: September 2008

February 16, 2006
September 29, 2008
February 2006
September 2006   (final data collection date for primary outcome measure)
Assessment of treatment compliance by recording of drug accountability
Same as current
Complete list of historical versions of study NCT00293046 on Archive Site
Recording of adverse events
Same as current
Not Provided
Not Provided
Assessment of Grazax® Treatment Compliance
A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Biological: ALK Grass tablet - use of compliance device
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2007
September 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Grass pollen induced rhinoconjunctivitis
  • Males and females, 18-65 years of age
  • Positive skin prick test

Exclusion Criteria:

  • Previous treatment with grass pollen allergen
18 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
ALK-Abelló A/S
Not Provided
Study Director: Kim Simonsen, MD ALK-Abelló A/S
ALK-Abelló A/S
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP